INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab

Naiem T. Issa, Shawn Kwatra, Ali Shahbaz, Leon Kircik

Open source

DOI
10.36849/jdd.015471
Published
2026-08-01
Container
Journal of Drugs in Dermatology
Publisher
SanovaWorks
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.36849/jdd.015471,
  title = {INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab},
  author = {Naiem T. Issa and Shawn Kwatra and Ali Shahbaz and Leon Kircik},
  year = {2026},
  journal = {Journal of Drugs in Dermatology},
  doi = {10.36849/jdd.015471},
  url = {https://doi.org/10.36849/jdd.015471}
}

RIS

TY  - JOUR
TI  - INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab
AU  - Naiem T. Issa
AU  - Shawn Kwatra
AU  - Ali Shahbaz
AU  - Leon Kircik
PY  - 2026
JO  - Journal of Drugs in Dermatology
DO  - 10.36849/jdd.015471
UR  - https://doi.org/10.36849/jdd.015471
ER  - 

APA

Issa, N. T., Kwatra, S., Shahbaz, A., & Kircik, L. (2026). INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.015471

Source records